Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07442513
PHASE3

Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT

Sponsor: First Affiliated Hospital of Zhejiang University

View on ClinicalTrials.gov

Summary

This study employs a prospective, randomized, double-blind, placebo-controlled design. It aims to compare the efficacy of etamsylate versus placebo in preventing bleeding complications in patients with thrombocytopenia following hematopoietic stem cell transplantation.

Official title: Comparison of Etamsylate Versus Placebo to Prevent Bleeding in Hematopoietic Stem Cell Transplantation Recipients:a Randomized, Double-blind, Phase 3, Clinical Study

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

404

Start Date

2025-12-16

Completion Date

2027-10-31

Last Updated

2026-03-02

Healthy Volunteers

No

Interventions

DRUG

etamsylate

etamsylate Injection, administer by intravenous infusion, diluted with 100ml of 0.9% Sodium Chloride Injection, twice daily.

DRUG

Placebo

0.9% Sodium Chloride Injection, 100 ml, twice daily, intravenous drip

Locations (1)

The First Affiliated Hospital, College of Medicine, Zhejiang University

Hangzhou, Zhejiang, China